Tralokinumab bei AD im Head-and-Neck-Bereich: Langzeit-Daten

CMECME-Fortbildungen

Fachrichtungen

Kooperationspartner

Anmelden Registrieren

Anmelden Registrieren

STREAMED UP ist die führende medizinische Videoplattform für Online Fortbildung, um immer auf dem neuesten Stand zu sein.

Kontakt aufnehmen

Direktnavigation

Suche

CME-Fortbildungen Kooperationspartner Partner

Über uns

News Jobs Impressum Datenschutzerklärung Barrierefreiheitserklärung Häufige Fragen & Antworten

Fachrichtungen

Allgemeinmedizin Fortbildung Dermatologie Fortbildung Nephrologie Fortbildung Neurologie Fortbildung Pneumologie Fortbildung

Alle Fachrichtungen

Inhalt

Eine kombinierte Analyse der Phase-3-Studien ECZTRA 1 & 2 und der Langzeitverlängerung ECZTEND zeigt: Tralokinumab kontrolliert die atopische Dermatitis im Head-and-Neck-Bereich über bis zu 4 Jahre wirksam. Nach 4 Jahren erreichten 86,1 % der Patient:innen einen H&N-EASI-Score ≤ 1. Paradoxe Erytheme traten bei nur 1 % auf und bildeten sich in über 70 % der Fälle unter Therapie zurück. Die 5-Jahres-Daten (ISAD 2025) bestätigen die Langzeitstabilität.

Quellen

[1]

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1)

https://clinicaltrials.gov/study/NCT03131648

[2]

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2)

https://clinicaltrials.gov/ct2/show/NCT03160885

[3]

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

https://clinicaltrials.gov/ct2/show/NCT03363854

[4]

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

https://clinicaltrials.gov/ct2/show/NCT03556592

[5]

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)

https://clinicaltrials.gov/ct2/show/NCT03562377

[6]

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

https://clinicaltrials.gov/ct2/show/NCT03526861

[7]

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (ECZTRA 7)

https://clinicaltrials.gov/ct2/show/NCT03761537

[8]

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (ECZTRA 8)

https://clinicaltrials.gov/ct2/show/NCT04587453

[9]

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function (TraSki)

https://clinicaltrials.gov/ct2/show/NCT04556461

[10]

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

https://clinicaltrials.gov/ct2/show/NCT03587805

[11]

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

https://clinicaltrials.gov/ct2/show/NCT05388760

[12]

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (TRAPEDS 2)

https://clinicaltrials.gov/study/NCT06311682

[13]

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

https://clinicaltrials.gov/study/NCT05958407.

Fachrichtungen

Allergologie

Allgemeinmedizin/Praktische Internistische Medizin

Dermatologie

Kanal

Partner

Kooperationspartner

Weitere Inhalte

Indikationen

Atopische Dermatitis

Atopische Dermatitis (AD)

Wirkstoffe

Tralokinumab

Schlagworte

5-Jahres-Daten

Biologikum

EASI Score

Ekzem

Gesichtsrötung

H&N-EASI

IL-13

IL-22

Kopf-Hals-Bereich

Langzeitstudie

Lebensqualität

monoklonaler Antikörper

Neurodermitis

paradoxes Erythem

Sicherheitsprofil

Typ-2-Inflammation

Verlängerungsstudie

Quellen

[1]

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1)

https://clinicaltrials.gov/study/NCT03131648

[2]

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2)

https://clinicaltrials.gov/ct2/show/NCT03160885

[3]

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

https://clinicaltrials.gov/ct2/show/NCT03363854

[4]

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

https://clinicaltrials.gov/ct2/show/NCT03556592

[5]

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)

https://clinicaltrials.gov/ct2/show/NCT03562377

[6]

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

https://clinicaltrials.gov/ct2/show/NCT03526861

[7]

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (ECZTRA 7)

https://clinicaltrials.gov/ct2/show/NCT03761537

[8]

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (ECZTRA 8)

https://clinicaltrials.gov/ct2/show/NCT04587453

[9]

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function (TraSki)

https://clinicaltrials.gov/ct2/show/NCT04556461

[10]

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

https://clinicaltrials.gov/ct2/show/NCT03587805

[11]

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

https://clinicaltrials.gov/ct2/show/NCT05388760

[12]

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (TRAPEDS 2)

https://clinicaltrials.gov/study/NCT06311682

[13]

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

https://clinicaltrials.gov/study/NCT05958407.